---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-003577"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:35:48.862105+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Genprex gets Australian patent acceptance for Reqorsa+PD-L1; adds trial site

## Summary
- IP Australia issued Notice of Acceptance on Feb 5, 2026 for patent covering Reqorsa + PD-L1 antibodies in cancer.
- Opened additional Acclaim-3 clinical trial site at University of Kentucky; plans more sites to expand enrollment.
- Acclaim-3 Phase 2 expansion targets ~50 patients; interim analysis after 25th patient expected in H2 2026.
- Patent already granted in US and Korea; pending in Europe, Canada, Brazil, China, and Israel.

## SEC filing metadata
- accession: 0001437749-26-003577
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926003577/0001437749-26-003577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926003577/gnpx20260209_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-003577
- JSON: https://secwatch.observer/filing/0001437749-26-003577.json
- Plain text: https://secwatch.observer/filing/0001437749-26-003577.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.